Exagen Diagnostics, Inc. is a leader in the discovery and development of genomic marker tests that assist physicians with disease diagnosis, prognosis and treatment response. Headquartered in Albuquerque, New Mexico, with an office in San Diego, CA, Exagen Diagnostics, Inc. is a molecular diagnostics company focused on identifying and developing genomic marker sets. These marker sets are used to create laboratory tests for diagnosis, prognosis, and predictive treatment response across a number of disease categories. Exagen’s current emphasis is on rheumatology and lupus. Exagen is a patient focused, discovery driven, CLIA registered, CAP certified laboratory with a growing menu of proprietary, internally developed tests. The Company is committed to personalized medicine, with tests specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management. Exagen Diagnostics went public in September 2019 (NASDAQ: XGN).